363 related articles for article (PubMed ID: 20349059)
1. RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells.
Borkner L; Kaiser A; van de Kasteele W; Andreesen R; Mackensen A; Haanen JB; Schumacher TN; Blank C
Cancer Immunol Immunother; 2010 Aug; 59(8):1173-83. PubMed ID: 20349059
[TBL] [Abstract][Full Text] [Related]
2. siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions.
Iwamura K; Kato T; Miyahara Y; Naota H; Mineno J; Ikeda H; Shiku H
Gene Ther; 2012 Oct; 19(10):959-66. PubMed ID: 22113316
[TBL] [Abstract][Full Text] [Related]
3. Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity.
Sierro SR; Donda A; Perret R; Guillaume P; Yagita H; Levy F; Romero P
Eur J Immunol; 2011 Aug; 41(8):2217-28. PubMed ID: 21538347
[TBL] [Abstract][Full Text] [Related]
4. Interaction of programmed death-1 and programmed death-1 ligand-1 contributes to testicular immune privilege.
Cheng X; Dai H; Wan N; Moore Y; Vankayalapati R; Dai Z
Transplantation; 2009 Jun; 87(12):1778-86. PubMed ID: 19543053
[TBL] [Abstract][Full Text] [Related]
5. B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer.
Liu Y; Zeng B; Zhang Z; Zhang Y; Yang R
Clin Immunol; 2008 Dec; 129(3):471-81. PubMed ID: 18790673
[TBL] [Abstract][Full Text] [Related]
6. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.
Blank C; Gajewski TF; Mackensen A
Cancer Immunol Immunother; 2005 Apr; 54(4):307-14. PubMed ID: 15599732
[TBL] [Abstract][Full Text] [Related]
7. Expression of programmed-death receptor ligands 1 and 2 may contribute to the poor stimulatory potential of murine immature dendritic cells.
Chen C; Qu QX; Huang JA; Zhu YB; Ge Y; Wang Q; Zhang XG
Immunobiology; 2007; 212(3):159-65. PubMed ID: 17412283
[TBL] [Abstract][Full Text] [Related]
8. Reviving exhausted T lymphocytes during chronic virus infection by B7-H1 blockade.
Yao S; Chen L
Trends Mol Med; 2006 Jun; 12(6):244-6. PubMed ID: 16650803
[TBL] [Abstract][Full Text] [Related]
9. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells.
Latchman YE; Liang SC; Wu Y; Chernova T; Sobel RA; Klemm M; Kuchroo VK; Freeman GJ; Sharpe AH
Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10691-6. PubMed ID: 15249675
[TBL] [Abstract][Full Text] [Related]
10. PD-L1/PD-1 signal deficiency promotes allogeneic immune responses and accelerates heart allograft rejection.
Wang W; Carper K; Malone F; Latchman Y; Perkins J; Fu Y; Reyes J; Li W
Transplantation; 2008 Sep; 86(6):836-44. PubMed ID: 18813109
[TBL] [Abstract][Full Text] [Related]
11. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.
Kaplan JM; Yu Q; Piraino ST; Pennington SE; Shankara S; Woodworth LA; Roberts BL
J Immunol; 1999 Jul; 163(2):699-707. PubMed ID: 10395660
[TBL] [Abstract][Full Text] [Related]
12. PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T-cell responses in EAE.
Schreiner B; Bailey SL; Shin T; Chen L; Miller SD
Eur J Immunol; 2008 Oct; 38(10):2706-17. PubMed ID: 18825752
[TBL] [Abstract][Full Text] [Related]
13. Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation.
Kuipers H; Muskens F; Willart M; Hijdra D; van Assema FB; Coyle AJ; Hoogsteden HC; Lambrecht BN
Eur J Immunol; 2006 Sep; 36(9):2472-82. PubMed ID: 16917960
[TBL] [Abstract][Full Text] [Related]
14. Co-inhibitory role of T-cell-associated B7-H1 and B7-DC in the T-cell immune response.
Seo SK; Seo HM; Jeong HY; Choi IW; Park YM; Yagita H; Chen L; Choi IH
Immunol Lett; 2006 Feb; 102(2):222-8. PubMed ID: 16236366
[TBL] [Abstract][Full Text] [Related]
15. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.
Iwai Y; Ishida M; Tanaka Y; Okazaki T; Honjo T; Minato N
Proc Natl Acad Sci U S A; 2002 Sep; 99(19):12293-7. PubMed ID: 12218188
[TBL] [Abstract][Full Text] [Related]
16. Altered availability of PD-1/PD ligands is associated with the failure to control autoimmunity in NOD mice.
Yadav D; Hill N; Yagita H; Azuma M; Sarvetnick N
Cell Immunol; 2009; 258(2):161-71. PubMed ID: 19497561
[TBL] [Abstract][Full Text] [Related]
17. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.
Butte MJ; Keir ME; Phamduy TB; Sharpe AH; Freeman GJ
Immunity; 2007 Jul; 27(1):111-22. PubMed ID: 17629517
[TBL] [Abstract][Full Text] [Related]
18. PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis.
Carter LL; Leach MW; Azoitei ML; Cui J; Pelker JW; Jussif J; Benoit S; Ireland G; Luxenberg D; Askew GR; Milarski KL; Groves C; Brown T; Carito BA; Percival K; Carreno BM; Collins M; Marusic S
J Neuroimmunol; 2007 Jan; 182(1-2):124-34. PubMed ID: 17182110
[TBL] [Abstract][Full Text] [Related]
19. Keratinocyte-associated B7-H1 directly regulates cutaneous effector CD8+ T cell responses.
Ritprajak P; Hashiguchi M; Tsushima F; Chalermsarp N; Azuma M
J Immunol; 2010 May; 184(9):4918-25. PubMed ID: 20363965
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+ cytotoxic T cells.
Waeckerle-Men Y; Starke A; Wüthrich RP
Nephrol Dial Transplant; 2007 Jun; 22(6):1527-36. PubMed ID: 17339272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
